Demonstrated Safety and Tolerability
ORACEA® Capsules Provide Multiple Benefits Over Doxycycline 100 mg1,2
ORACEA Capsules | Doxycycline 100 mg | |
---|---|---|
Favorable GI tolerability compared to 100 mg1
|
||
No evidence of bacterial resistance2In a 9-month study | ||
No photosensitivity or vaginal candidiasis reported in controlled clinical studies2 |
As with other tetracycline-class products, ORACEA Capsules should not be used in people with known hypersensitivity to any of the tetracyclines and may cause fetal harm when administered to pregnant women. patients taking ORACEA Capsules should minimize or avoid exposure to natural or artificial sunlight.3
- Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576.
- Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802.
- ORACEA® [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; 2013.
Visible Results
ORACEA Capsules are formulated for an effective anti-inflammatory response
Learn More